Regulatory Affairs Services Provider in Sri Lanka
DDReg provides regulatory affairs services in Sri Lanka for pharmaceutical, medical device, and biologics companies. Our consultants manage NMRA registration submissions, coordinate Medicines Evaluation Committee (MEC) review processes, support GMP site licensing for foreign manufacturers, and maintain post-registration compliance across Sri Lanka's growing healthcare market.
Sri Lanka's Regulatory Framework for Medicines and Medical Devices
The National Medicines Regulatory Authority (NMRA) is the independent regulatory body established under the National Medicines Regulatory Authority Act No. 5 of 2015. The NMRA operates under the Ministry of Health and holds authority over the registration, licensing, and surveillance of medicines, medical devices, borderline products, clinical trials, and cosmetics. The National Medicines Quality Assurance Laboratory (NMQAL) functions within the NMRA's purview and conducts systematic product quality testing.
Scientific review of all registration applications is conducted by the Medicines Evaluation Committee (MEC), a statutory body formed under the NMRA Act. The MEC comprises experts drawn from medicine, pharmacy, and allied health disciplines. It meets monthly to review dossiers submitted for marketing authorisation and to make policy decisions on registration procedures. Separate evaluation committees exist for medical devices (MDEC) and borderline products (BPEC).
Sri Lanka's market is import-dependent for approximately 90% of its medicines, with India as the dominant supplier. Approximately 15 local manufacturers operate domestically, including one multinational. The NMRA Act 2015 introduced price declaration requirements: applicants declare an intended retail price at registration, and NMRA may negotiate or impose price controls. A maximum retail price framework has been applied to 48 essential medicines, intraocular lenses, and cardiac stents.
Regulatory Authorities in Sri Lanka
| Authority / Body | Role |
|---|---|
| NMRA | Sole regulatory authority for medicines, medical devices, borderline products, clinical trials, and cosmetics; issues marketing authorisations, manufacturing licences, and wholesale/retail licences |
| MEC (Medicines Evaluation Committee) | Statutory expert committee that conducts monthly scientific review of all medicine registration applications; makes marketing authorisation and policy decisions |
| MDEC (Medical Devices Evaluation Committee) | Statutory expert committee for medical device registration evaluation |
| NMQAL (National Medicines Quality Assurance Laboratory) | NMRA-supervised laboratory; conducts post-market quality testing and batch analysis of registered products |
| Reference Regulatory Authorities (SRAs) | NMRA recognises US FDA, Health Canada, EMA, MHRA, MPA Sweden, CBG-MEB Netherlands, TGA Australia, and Medsafe New Zealand as reference authorities for new molecule submissions |
Regulatory Consulting in Sri Lanka - Services Portfolio
DDReg's pharmaceutical regulatory services in Sri Lanka cover all registration categories, manufacturing site licensing, and post-approval lifecycle management.
-
Pharmaceutical Registration - New Applications
-
Manufacturing Site Licensing - Foreign Manufacturers
-
Medical Device Registration in Sri Lanka
-
Clinical Trial Authorisation
-
Post-Registration Lifecycle Management
NMRA Registration Services Sri Lanka - Submission Process
DDReg manages Sri Lanka regulatory submissions through structured phases:
-
Pre-Submission Preparation
-
Dossier Preparation
-
MEC Scientific Review
-
Registration Certificate and Market Access
Sri Lanka Regulatory Approval Timelines
Timelines depend on product category, dossier completeness, and MEC scheduling. MEC meets monthly, so submission timing relative to committee dates affects active review start:
| Product / Procedure | Typical Timeline |
|---|---|
| New Chemical Entity (NCE) | 18–24 months from accepted submission |
| New Dosage Form (NDF) | 12–18 months |
| Generic pharmaceutical (standard) | 9–15 months |
| Generic - with bioequivalence study requirement | 12–18 months (study planning included) |
| Biologic / biosimilar | 18–30 months |
| WHO Collaborative Registration Procedure | 90 days (from accepted submission; stop clocks apply) |
| Medical device - provisional registration | 6–12 months (two-stage: sample licence then evaluation) |
| Medical device - full registration | 12–18 months minimum |
| Manufacturing site approval (inspection-exempt country) | 3–6 months |
| Manufacturing site approval (NMRA inspection required) | 9–18 months (inspection scheduling included) |
| Variation (minor) | 3–6 months |
| Variation (major) | 6–12 months |
Note: MEC meets monthly - applications submitted after a committee cycle wait for the next meeting. Additional information requests pause the review clock. DDReg prepares complete dossiers to avoid query cycles and coordinates submission timing to minimise committee queue delays.
Sri Lanka Regulatory Affairs Partner - DDReg's Expertise
Our consultants understand NMRA's July 2024 registration guidelines, the CTD module requirements specific to Sri Lanka, and how MEC evaluates the five statutory criteria - quality, safety, efficacy, need, and cost-effectiveness. This knowledge shapes dossier preparation and the sequence of Module 1 administrative documentation, which differs from other markets in its SRA evidence and price declaration requirements.
NMRA's list of eight recognised reference authorities is fixed and well-defined. DDReg assesses which SRA approval is available or most efficiently obtainable for a given product, and confirms the two-year post-marketing experience requirement is satisfied before Sri Lanka submission preparation begins - preventing applications that will not pass initial screening.
Manufacturing site approval is a precondition for product registration in Sri Lanka. DDReg manages site master file preparation, WHO GMP certificate currency confirmation, and - for manufacturers outside the nine inspection-exempt countries - coordinates NMRA inspection scheduling and preparation. This pathway is managed before dossier work begins to avoid sequence errors that extend overall project timelines.
For WHO-prequalified pharmaceutical products, the WHO Collaborative Registration Procedure offers a 90-day decision pathway. DDReg coordinates the manufacturer's access to this procedure, manages the WHO extranet documentation requirements, and tracks the stop-clock periods that apply when NMRA requests clarification.
Sri Lanka's medical device registrations services require sequential management sample import licence first, then testing under that licence, then formal registration application with MDEC. DDReg manages both stages and the translation of Instructions for Use into Sinhala and Tamil, which is an NMRA mandatory requirement distinct from most other markets.
Global Reach Explorer
Find Your Solution
Our Regulatory Affairs Consulting Services in Sri Lanka portfolio covers:
Regulatory Strategies
The pharmaceutical industry operates under stringent regulations to ensure the safety, efficacy, and quality...
New Product Marketing Authorizations
Navigating marketing authorization is a complex and time-sensitive process. Every country has its own regulatory framework...
Gap Analysis and Remediation
In the highly regulated pharmaceutical industry, maintaining compliance is critical. Regulatory gap analysis helps identify deficiencies in technical documentation...
Regulatory Due Diligence
Regulatory issues arise unexpectedly and can create significant strain on a company’s resources. As such, it is advisable for all companies to carry out regular and frequent regulatory due diligence and audits...
API & DMF services
Drug Master Files (DMFs) contain confidential and detailed information regarding API processes—from manufacturing to storage. DDReg’s DMF Services deliver precise...
CMC Advisory
DDReg’s CMC services are dedicated to assisting customers in developing robust and an efficient regulatory strategy through all development phases - authoring...
Post Approval Life Cycle Management
Maximize product value with expert pharma lifecycle management. Our dedicated team ensures that your product remains on shelves and compliant with ever-evolving regulations through strategic post-approval management...
Certification Services
Partner with DDReg to navigate the complex process of regulatory certification of pharmaceutical...
ANDA and MA Holder Services
Our comprehensive services support both Abbreviated New Drug Applications (ANDA) and Marketing Authorization processes.
Publishing & Submission
Our comprehensive digital solution transforms traditional paper dossier submissions into a streamlined electronic format. With robust infrastructure and cutting‐edge management processes...
